Figure 7
CKD-506 alleviated depression-like behavior, as evaluated using the tail suspension test. Additionally, CKD-506 upregulated the acetylated α-tubulin level in the brain. Mice were orally administered CKD-506 (30 mg/kg bodyweight) and fingolimod (0.3 mg/kg bodyweight) daily from days 6 to 8 post-myelin oligodendrocyte glycoprotein35–55 immunization (a–c). Tail suspension test (n = 12 per group for the non-immunized groups; n = 13 per group for the other groups) (a) and analysis of acetylated α-tubulin expression (n = 3 per group) (b) were performed during the pre-symptomatic stage on day 8 post-induction. (c) Protein bands of acetylated α-tubulin and α-tubulin are shown. Data are presented as mean ± SD and analyzed using one-way ANOVA, followed by Dunnett’s post-hoc test. #p < 0.05, non-immunized groups versus vehicle group; *p < 0.05 and **p < 0.01, drug-treated group versus vehicle group. N, non-immunized groups; V, vehicle group; Fin, fingolimod (0.3 mg/kg bodyweight)-treated group.
